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Long-term outcome in pulmonary arterial
hypertension: a plea for earlier parenteral
prostacyclin therapy
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ABSTRACT: The present review aims to examine the effect of specific drugs on long-term
outcome of pulmonary arterial hypertension (PAH), to critically review the available data, and to
derive useful information for daily patient care.
PAH is an intrinsic disease of the pulmonary circulation with a malignant evolution as a
consequence of progressive right heart failure. Without specific therapy, median survival is only
2.8 yrs. The intravenous prostacyclin analogue epoprostenol is the only treatment with a
demonstrated effect on survival, observed during a single 12-week randomised placebo-
controlled trial. Three long-term observational studies have also shown that median survival is
raised above 6 yrs with this therapy. Subcutaneous treprostinil appears to have similar beneficial
effects on survival, as reported in two long-term observational studies. This is not the case for
inhaled iloprost, as shown in one study in which a high proportion of patients needed the addition
of, or the switch to, another therapy. Among the oral agents, long-term data have only been
published for bosentan. The three studies including patients from expert centres also showed
very good survival data, but again with a broad use of combination therapy. In less expert hands,
with limited access to more complex therapies, reported survival seems much worse. In these
studies, baseline New York Heart Association class and 6-min walk distance are repeatedly shown
to be important predictors of survival. Finally, there is emerging data that prostanoid therapy
results in a tendency to normalise C-reactive protein levels, a factor associated with improved
long-term outcomes.
KEYWORDS: Endothelin receptor antagonists, outcome, prostacyclin analogues, pulmonary
arterial hypertension
P
ulmonary arterial hypertension (PAH) is an
intrinsic, pre-capillary pulmonary arterio-
pathy characterised by intima fibrosis,
media hypertrophy, matrix proliferation and plexo-
genic lesions. It includes an idiopathic (IPAH) and
a familial/inherited form, as well as pulmonary
hypertension associated with connective tissue
disease, congenital systemic-to-pulmonary shunts,
portal hypertension, HIV and the use of drugs or
anorexigens.
In the pre-prostacyclin era, the median survival of
untreated patients with IPAH was 2.8 yrs [1],
placing IPAH among the most malignant diseases
of the middle-aged individual. The 12-week epo-
prostenol pivotal trial was the first step forward,
showing a lower death rate in patients treated with
epoprostenol compared with placebo [2]. However,
none of the more recent randomised controlled
trials have been able to confirm this trend.
However, by combining these trials in a meta-
analysis involving a total of 3,140 patients, a
significant mortality reduction was recently
demonstrated [3].
Current PAH-specific therapies target three path-
ways: the 1) prostacyclin and 2) nitric oxide
pathways, with cyclic adenosine monophosphate
(cAMP) and cyclic guanosine monophosphate
(cGMP) as respective second messengers, both
acting as vasodilators and inhibitors of smooth
muscle cell proliferation; and 3) the endothelin
(ET)-1 pathway, acting via a G protein-coupled
receptor as a vasoconstrictor and a proliferating
agent. Prostacyclin analogues include epoproste-
nol, exclusively used intravenously because of its
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very short half-life, and more stable compounds, such as
treprostinil, which can be used subcutaneously, intravenously,
inhaled or orally, iloprost for inhaled and i.v. use, and
beraprost for oral use. Inhibitors of cGMP phosphodiesterase
5, such as sildenafil and the longer-acting tadalafil, are orally
administrated and used to increase intracellular concentrations
of cGMP. The selective ETA- (sitaxsentan and ambrisentan)
and dual ETA- and ETB-receptor (bosentan) antagonists have
been developed for oral use.
The regulatory approval and subsequent clinical use of these
agents is based on trials of between 12 and 16 weeks’ duration
demonstrating improvements in exercise capacity. The present
review discusses current evidence exceeding this time interval.
Given the paucity of randomised trials, conclusions are more
difficult. We ask, therefore, do we really improve long-term
survival in PAH? And, if so, what may be the optimal strategy?
LONG-TERM PLACEBO-CONTROLLED STUDIES
The only published long-term, placebo-controlled study in PAH
is the American beraprost study [4]. It was a 1-yr, multicentre,
double-blind, randomised, placebo-controlled trial, which
included 116 PAH patients and looked at disease progression,
6-min walk distance (6MWD), peak oxygen consumption, Borg
dyspnoea score, haemodynamics, symptoms and quality of life.
Baseline characteristics of the study population were a mean age
of 42¡2 yrs, a 6MWD of 439¡11 m and a New York Heart
Association (NYHA) functional class II to III repartition of 52.5
to 47.5%. Beraprost was administrated four times daily at an
increasing mean dose of 71 mg at 3 months, 92 mg at 6 months
and 107 mg at 12 months. In this study, the initial improvement
in exercise capacity was no longer significant at 1 yr. The
beraprost-treated patients had improved 6MWD by 22 m from
baseline at 3 months (p50.010) and by 31 m at 6 months
(p50.016) compared with placebo, but not at 9 or 12 months.
There was also no effect on haemodynamics at 12 months.
Beside this, some medium-term data for bosentan-treated
patients exists. A 48 patient subset of the BREATHE-1
(Bosentan Randomized Trial of Endothelin Antagonist
Therapy) 16-week pivotal trial [5] entered a second blinded
period of 12 weeks. In the 35 patients who continued bosentan
blinded treatment, there was a slight decrease in 6MWD at
28 weeks that, even if it was not significant, was somewhat
worrisome (unpublished data).
Instead of increasing placebo-controlled study duration, rando-
mised withdrawal is another way to show durability of drug
effect. This approach, somewhat controversial for a life-
sustaining therapy, has been cautiously used for epoprostenol,
showing that down-titration after a mean of 3.4 yrs of treatment
was uniformly accompanied by clinical deterioration [6].
OBSERVATIONAL STUDIES
To compensate for the scarcity of long-term controlled data on
drug efficacy in PAH, large observational studies have been
proposed in order to evaluate long-term outcome. These
studies are presently available for most of the specific PAH
medications (epoprostenol, treprostinil, iloprost and bosentan).
However, we have to be aware of the numerous limitations of
these studies: they were open-label studies, and there were
patient drop-outs, treatment changes and an absence of
contemporary control groups.
Focusing on long-term data with i.v. epoprostenol, we identified
three major studies (table 1). The first, by BARST et al. [7], is an
open-label follow-up of 18 patients previously included in the
initial randomised controlled trial from RUBIN et al. [10]. The
second, by SITBON et al. [8], and the third, by MCLAUGHLIN et al.
[9], are much larger single-centre series of patients, from the
French and US reference centres in Clamart and Chicago, IL,
respectively. In the studies by BARST et al. [7] and SITBON et al. [8],
survival of epoprostenol-treated patients was compared to a
matched historical cohort, while in the study by MCLAUGHLIN et
al. [9] survival was predicted from the d’Alonzo equation,
derived from the US National Institutes of Health (NIH) registry
population [1]. This equation has been largely used to calculate
survival on the basis of haemodynamic parameters (mean
TABLE 1 Long-term response to intravenous epoprostenol
BARST [7] SITBON [8] MCLAUGHLIN [9]
Drug Epoprostenol Epoprostenol Epoprostenol




Single-centre series (USA) versus predicted
survival (NIH registry)
Patients 18 IPAH 178 IPAH 162 IPAH
End-points 6MWD, haemodynamics, death NYHA, 6MWD, PVR, death NYHA, haemodynamics, death
Baseline CI L?min-1?m-2 1.8¡0.6 1.96¡0.56 1.82¡0.57
Baseline 6MWD m 264¡160 240¡146
NYHA FC II/III–V % 6/94 0/100 0/100
Dose ng?kg-1?min-1 1 yr: 18¡11 3 months: 14¡4 17 months: 35¡30
2 yrs: 37¡21 1 yr: 21¡7 30 months: 52¡35
3 yrs: 53¡30 41 months: 33¡11 43 months: 55¡42
Age yrs 36¡13 43¡13 42
Data are presented as mean¡SD unless otherwise stated. CI: cardiac index; 6MWD: 6-min walk distance; NYHA: New York Heart Association; FC: functional class; NIH:
National Institutes of Health; IPAH: idiopathic pulmonary arterial hypertension; PVR: pulmonary vascular resistance.
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pulmonary arterial pressure, cardiac index and right atrial
pressure). These three studies included IPAH patients with
severe disease, as evidenced by their poor cardiac index
,2 L?min-1?m-2, poor baseline 6MWD of,250 m and the almost
exclusive NYHA class III and IV inclusion. As a consequence of
the well-known tolerance to prostanoid, epoprostenol dose was
progressively increased to 30 ng?kg-1?min-1 at 3 yrs in the French
cohort and 50 ng?kg-1?min-1 in the US series. Survival data at 1, 2
and 3 yrs are reported in table 2. BARST et al. [7] reported a
significant survival improvement in epoprostenol-treated
patients when compared with the historical control group
(p50.045), and the median survival reached more than 6 yrs.
These results were confirmed in the SITBON et al. [8] and
MCLAUGHLIN et al. [9] series, in which survival was similar
despite the substantial differences in dosage. Both studies also
confirmed the importance of the baseline NYHA functional class
in predicting the outcome of epoprostenol-treated IPAH
patients, as originally shown in the NIH registry untreated
population [1]. However, despite the poorer prognosis, median
survival in class IV patients was prolonged from 6 months to
.3 yrs in both cohorts.
More recently, two retrospective studies using subcutaneous
treprostinil in patients with PAH have been published (table 3).
The first, by LANG et al. [14], described 122 patients, including 99
with PAH and 23 with chronic thromboembolic pulmonary
hypertension, started with treprostinil in three European centres.
The second, by BARST et al. [13], assessed 860 PAH patients,
including patients previously enrolled in the pivotal trials as well
as de novo patients from the USA. At baseline, patients had less
severe disease than those of the epoprostenol series, as demon-
strated by their baseline 6MWD of ,300 m and cardiac index
.2 L?min-1?m-2, the predominance of NYHA class III patients
and the inclusion of some class II patients. Within 3 yrs, the
treprostinil dose was progressively increased to 40 ng?kg-1?min-1
in both the European and the predominantly US cohorts. Survival
data at 1, 2 and 3 yrs are reported in table 2. LANG et al. [14]
reported a 65-m increase in 6MWD and an improvement in
NYHA class at 1 yr, both of which were maintained at 2 and
3 yrs. This contrasts with the modest improvements seen in the
pivotal 12-week study [23], in which the median placebo-
corrected increase in 6MWD was only 16 m, reflecting the
significant dosing limitations which resulted from local infusion
pain. In addition, survival among the 32 IPAH patients was
significantly better than predicted and comparable with the
survival obtained with i.v. epoprostenol. The favourable long-
term data were confirmed in the 332 IPAH patients of the study
by BARST et al. [13], showing that survival of patients receiving
treprostinil in monotherapy was not different from that of the
entire cohort. Oral therapy, predominantly bosentan, but also
sildenafil, was added in 18% and 15% of the LANG et al. [14] and
BARST et al. [13] studies, respectively. Drop-out due to infusion
site pain was observed in 5% of the patients included in the LANG
et al. [14] study and in 23% of the patients included in the larger
cohort studied by BARST et al. [13], highlighting the importance of
dedicated centres for efficient patient support. BARST et al. [13]
also confirmed the predictive value of baseline NYHA functional
class, as well as baseline 6MWD, pulmonary vascular resistance
and mixed venous oxygen saturation, in the outcome of
treprostinil-treated PAH patients. Having a baseline NYHA class
IV, a 6MWD ,295 m, an indexed pulmonary vascular resistance
.30 WU?m-2, or a mixed venous oxygen saturation ,55%, was
associated with a 52–59% risk of dying within 3 yrs [24].
TABLE 2 Long-term survival in pulmonary arterial hypertension (PAH)
Drug Patients n Type CI L?min-1?m-2 NYHA 6MWD m OA % Survival % Comb. %
1 yr 2 yrs 3 yrs
D’ALONZO [1] Conservative treatment 194 IPAH 20 68 48
JING [11] Conservative treatment 72 IPAH 2.76¡0.7 50 68 57 39
CHRISTIE [12] Lung transplant 970 IPAH 67 61 57
BARST [7] Epoprostenol 18 IPAH 1.90¡0.60 3.17¡0.5 264¡160 100 87 72 63
SITBON [8] Epoprostenol 178 IPAH 1.96¡0.56 3.33¡0.5 240¡146 85 70 63
MCLAUGHLIN [9] Epoprostenol 162 IPAH 1.82¡0.57 3.54¡0.5 88 76 63
BARST [13] Treprostinil 860 PAH 2.94¡0.5 87 78 71 15
LANG [14] Treprostinil 122 PAH/CTEPH 2.13¡0.66 3.20¡0.04 305¡11 95 89 71 18
OPITZ [15] Inhaled iloprost 76 IPAH 1.80¡0.81 2.86¡0.6 47 79 70 59 54
HOEPER [16] i.v. iloprost 79 PAH 1.70¡0.60 3.23¡0.4 287¡112 86 73 59
MCLAUGHLIN [17] Bosentan 169 IPAH 2.35¡0.80 2.99¡0.5 345¡87 96 89 86 30
HOEPER [18] Bosentan 123 PAH 2.10¡0.60 3.20¡0.4 308¡133 88 93 83 80 43
PROVENCHER [19] Bosentan 103 IPAH 2.39¡0.57 3.12¡0.3 319¡105 99 92 89 79 44
SANDOVAL [20] Atrial septostomy 15 IPAH 2.22¡0.46 3.57¡0.6 107¡127 100 87 87 87
RICH [21] Calcium channel blockers 17 IPAH (R) 2.60¡0.70 2.39¡0.5 74 94 94 94
SITBON [22] Calcium channel blockers 38 IPAH (LTR) 2.34¡1.0 380¡112 97 97 97
Data are presented as mean¡SD, unless otherwise stated. Summary of large cohorts treated with epoprostenol, treprostinil, iloprost and bosentan in comparison with
conservative treatment, lung transplantation, atrial septostomy and calcium channel blockers. CI: cardiac index; NYHA: New York Heart Association; 6MWD: 6-min walk
distance; OA: proportion of patients treated with oral anticoagulants; Comb.: proportion of patients started with combination or switched from therapy during the
observation period; IPAH: idiopathic PAH; CTEPH: chronic thromboembolic pulmonary hypertension; R: responders; LTR: long-term responders.
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Evidence for the use of the prostacyclin-analogue iloprost is
reliant upon two long-term studies: one by OPITZ et al. [15],
performed with inhaled administration and one by HOEPER et
al. [16] with i.v. administration. In most cases, i.v. administra-
tion became a second-line therapy for patients initially treated
with inhaled iloprost for a median of 12 months (table 4).
Whereas baseline 6MWD was not available in the cohort studied
by OPITZ et al. [15], most of the patients included were in NYHA
class II and III. Iloprost (100 mg) was administered as six
inhalations per day. In the cohort studied by HOEPER et al. [16],
patients were severely sick at the start of i.v. iloprost therapy,
with a baseline 6MWD of 228 m, a cardiac index,2 L?min-1?m-2
and a majority in NYHA class IV. Iloprost dose was increased to
2.6 ng?kg-1?min-1 at 6 months. Survival data at 1, 2 and 3 yrs are
reported in table 2. In the study by OPITZ et al. [15], only 20% of
the patients were still on iloprost monotherapy at 3 yrs. In the
study by HOEPER et al. [16], median survival was only 3 yrs from
diagnosis and 1 year from i.v. iloprost initiation, which does not
differ from survival without specific treatment [1]. However,
this study included a selection of patients with a mean
pulmonary vascular resistance .1,500 dyn?s?cm-5, who were
doing poorly on inhaled iloprost, and who were probably
underdosed with i.v. iloprost (dosage used in UK centres is
about 3.3 and 4.7 ng?kg-1?min-1 at 3 and 12 months, respectively).
TABLE 3 Long-term response to subcutaneous treprostinil
LANG [14] BARST [13]
Drug Treprostinil Treprostinil
Design 3-yr, multicentre, retrospective analysis 4-yr, multicentre, retrospective analysis;
other PAH therapies added as needed
Patients 99 PAH, 23 CTEPH 860 PAH
End-points 6MWD, NYHA FC, survival, event-free survival Survival, survival on monotherapy
Baseline CI L?min-1?m-2 2.13¡0.66
Baseline 6MWD m 305¡11
NYHA FC II/III/IV % 7/66/27 15/76/9
Dose ng?kg-1?min-1 1 yr: 26 1 yr: 26
2 yrs: 32 2 yrs: 36
3 yrs: 40 3 yrs: 42
4 yrs: 42
Age yrs 49 (12–81) 46 (5–84)
Data are presented as mean¡SD or mean (range), unless otherwise stated. CI: cardiac index; 6MWD: 6-min walk distance; NYHA: New York Heart Association; FC:
functional class; PAH: pulmonary arterial hypertension; CTEPH: chronic thromboembolic pulmonary hypertension.
TABLE 4 Long-term response to inhaled and intravenous iloprost
OPITZ [15] HOEPER [16]
Drug Inhaled iloprost i.v. iloprost
Design 5-yr, multicentre, prospective analysis 6-yr, multicentre, retrospective, second-line of
inhaled iloprost (95%, 12 months)
Patients 76 IPAH 79 PAH
End-points Survival, event-free survival (death, lung
transplant, i.v. therapy, start oral agents)
Survival, lung transplant-free survival
Baseline CI L?min-1?m-2 1.8¡0.81 Diagnosis: 1.7¡0.6
Onset i.v. iloprost: 1.5¡0.4
Baseline 6MWD m Diagnosis: 287¡112
Onset i.v. iloprost: 228¡114
NYHA FC II/III/IV % 24/67/9 Diagnosis: 0/77/23
Onset i.v. iloprost: 0/33/67
Mean dose 100 mg?day-1
in six inhalations (nebuliser)
1.8 ng?kg-1?min-1 at discharge
2.6 ng?kg-1?min-1 at 6 months
Age yrs 43¡0.1 47¡13
Data are presented as mean¡SD, unless otherwise stated. CI: cardiac index; 6MWD: 6-min walk distance; NYHA: New York Heart Association; FC: functional class; PAH:
pulmonary arterial hypertension; IPAH: idiopathic PAH.
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Nevertheless, this study confirmed the importance of baseline
6MWD and mixed venous oxygen saturation in predicting the
outcome of iloprost-treated patients with PAH.
Concerning oral agents, long-term data are only available for the
dual receptor antagonist bosentan (table 5). Three series have
been published: the one studied by MCLAUGHLIN et al. [17] is an
open-label follow-up of patients included in two randomised
controlled trials [5, 25]; those published by HOEPER et al. [18] and
PROVENCHER et al. [19] are single-centre series from Germany
and France, respectively. The MCLAUGHLIN et al. [17] and
PROVENCHER et al. [19] studies only included IPAH patients.
Patients were less sick than in the prostanoid studies, with
baseline 6MWD 300–350 m, and predominantly in NYHA class
III. They received the recommended dose of bosentan (125 mg
b.d.). Survival data at 1, 2 and 3 yrs are reported in table 2.
MCLAUGHLIN et al. [17] reported survival that was better than
predicted estimates, with a mortality of 5.5% per annum.
However, 30% of the patients were on combined therapy at
3 yrs. Similarly good survival data were confirmed in the two
other cohorts. The goal-oriented approach adopted by HOEPER et
al. [18], with additional drugs added every 2 to 6 months if pre-
defined goals were not attained (6MWD .380 m, peak oxygen
uptake .10.4 mL?min-1?kg-1 and peak systolic blood pressure
.120 mmHg), did not provide a survival advantage when
compared to the other two series. However, in the cohort
studied by PROVENCHER et al. [19] only 40% of the patients
remained on bosentan monotherapy at 3 yrs, a prostanoid being
added in patients with NYHA class .II, 6MWD ,250 m and
cardiac index,2.2 L?min-1?m-2. Only 3% of the patients stopped
bosentan because of elevated liver enzymes in this cohort.
COMPARISON OF THE DIFFERENT THERAPEUTIC
APPROACHES
Since no direct comparison between PAH-specific medications
has been performed, it is interesting to place in perspective the
survival data collected from the aforementioned long-term
observational studies (table 2). The first two rows display series
performed when no PAH-specific therapy was available in the
USA [1] and in China [11]. It should be emphasised that the
historical data obtained by D’ALONZO et al. [1], frequently
contested as a comparator, were reaffirmed by more recent
survival data from China where PAH-specific therapies are not
widely available. The third row displays the most recent survival
data concerning lung transplantation in PAH reported by the
International Society of Heart and Lung Transplantation [12].
Concerning the survival benefit raised by the PAH specific
therapies, it is notable that different series across different
countries or continents provided remarkably similar survival
data within each drug category: 63% at 3 yrs for epoprostenol,
71% for treprostinil, 59% for iloprost and 80% for bosentan
(table 2). It is also important to note that: 1) these positive
survival data were actually obtained with broad use of
combination therapies, especially concerning bosentan studies;
2) in comparison with the NIH historical group of patients,
anticoagulants were used in a larger extent in the most recent
series; and 3) less sick patients were included in the bosentan
series, as demonstrated by the cardiac index, NYHA class and
the 6MWD. This evolution precludes the comparison of oral
agent and parenteral prostanoid efficacy, although it is obvious
that more patients are surviving on monotherapy with
parenteral prostanoids (85%) then with oral agents (55%).
Despite being acceptable when compared with historical
controls, survival rates with PAH-specific drugs seem inferior
when those patients with severe symptoms are compared with
results after atrial septostomy [20]. However, these data need
to be confirmed by other studies. Moreover, the small group of
patients with reversible IPAH (,7%) who are long-term
responders to calcium channel blockers seem to have a
favourable prognosis, with survival .87% at 3 yrs [21, 22]
without the need for additional, more specific, agents.
REAL-LIFE EXPERIENCE WITH PAH THERAPIES
Beside these optimistic data, another perspective on current
therapeutic practices in PAH has been provided by Accredo, a
company which delivers different PAH-specific drugs to US
patients. They reported, at the 2008 congress of the Pulmonary
Hypertension Association, that an elevated proportion of
patients who were dying from PAH were on oral agent
monotherapy [26]. In a series of 821 patients, who were
TABLE 5 Long-term response to oral bosentan
MCLAUGHLIN [17] HOEPER [18] PROVENCHER [19]
Drug Bosentan Bosentan Bosentan
Design 4-yr, multicentre, extension study of
randomised controlled trials
Single-centre, prospective, uncontrolled Single-centre, retrospective analysis
Patients 169 IPAH 123 PAH 103 IPAH
End-points Survival Survival, lung transplant-free and i.v.
prostanoid-free survival
Survival
Baseline CI L?min-1?m-2 2.35¡0.80 2.1¡0. 6 2.39¡0.57
Baseline 6MWD m 345¡87 308¡133 319¡105
NYHA FC II/III/IV % 9/82/9 0/80/20 0/88/12
Dose 26125 mg 26125 mg 26125 mg
Age yrs 46¡16 52¡14 54¡16
Data are presented as mean¡SD, unless otherwise stated. CI: cardiac index; 6MWD: 6-min walk distance; NYHA: New York Heart Association; FC: functional class; PAH:
pulmonary arterial hypertension; IPAH: idiopathic PAH.
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initiated on bosentan between October 1 and December 31,
2004, overall survival at 3 yrs was only 64%, in comparison
with the previously reported 80% by the German and French
expert centres [18, 19]. From the 190 patients who died, 169
(89%) were on bosentan monotherapy, and only 11% were
treated with prostanoids before death. The vast majority of
them had never been referred to an expert centre.
The good survival data of patients treated with bosentan in
expert centres were obtained with a broad and undelayed use
of combination therapy including a prostanoid [18, 19]. In less
experienced hands, with limited access to combined therapies,
reported survival appears severely impaired.
ANTI-INFLAMMATORY EFFECTS OF PAH DRUGS AND
LONG-TERM SURVIVAL
Another appealing observation is the effect of prostanoids on
systemic inflammation. Prostacyclin analogues interact in
different ways with inflammatory cells [27]. However, the
relevance of this for the treatment of pulmonary hypertension
remained unknown until the following findings were reported:
1) circulating C-reactive protein (CRP) levels are increased in
PAH patients and are significantly higher in NYHA class III–
IV patients and in nonsurvivors; 2) patients with CRP levels
.5.0 mg?L-1 have a significantly lower survival rate and CRP is
an independent predictor of survival; and 3) patients normal-
ising their CRP levels under treatment, assigned as responders,
have a significantly higher survival rate (fig. 1a) [28]. It is
noteworthy that the proportion of patients treated with a
prostacyclin analogue was significantly higher among the
responders (55% versus 17%; fig. 1b). Patients undergoing
prostanoid therapy also displayed significantly lower CRP
levels (fig. 1c).
Since inflammation appears to play a role among the
pathological mechanisms of PAH [29], the anti-inflammatory
properties of prostanoids, illustrated by a tendency to normal-
ise CRP, may be a relevant finding.
CONCLUSION
In conclusion, there is a large body of very consistent evidence
for improved survival from long-term observational studies
performed in different centres and countries, accompanied by
a sustained benefit in 6MWD and NYHA functional class. The
latest series on oral therapy included patients with less severe
disease and more stable prevalent cases, which artificially
contributed to improved survival. Additionally, it seems that:
1) more patients are surviving on monotherapy with parenteral
prostanoids than with oral agents; 2) a large proportion of
patients who are dying are on monotherapy with oral agents
and not treated in reference centres with access to all therapies;
and 3) prostanoids seem to have a more pronounced anti-
inflammatory effect, with implications for the prognosis.
This emphasises the need to escalate treatment rapidly, to
promote treatment strategies including prostanoid use, and to
accelerate transfer to reference centres.
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FIGURE 1. Effect of pulmonary arterial hypertension-specific treatment on
systemic inflammation. a) Kaplan–Meyer survival curves for patients normalising
their C-reactive protein (CRP) levels under treatment (responders, i.e. CRP
f5 mg?L-1; ––––) versus nonresponders (i.e. CRP o5 mg?L-1; ??????) (p,0.05).
b) CRP levels in patients treated with prostacyclin analogues versus patients treated
with another drug (p50.01). ––––: geometric means. c) Proportion of patients
treated with prostacyclin analogues versus another drug among the responders (h)
and nonresponders (&) (p50.002). Reproduced from [28] with permission from the
publisher.
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